Skip to main content
Log in

Comment on: “Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence”

  • Letter to the Editor
  • Published:
Drug Safety Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 08 August 2016

The Original Article was published on 29 March 2016

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sinclair JM, Chambers SE, Shiles CJ, Baldwin DS. Safety and tolerability of pharmacological treatment of alcohol dependence: comprehensive review of evidence. Drug Saf. 2016;39(7):627–45.

    Article  CAS  PubMed  Google Scholar 

  2. Braillon A, Granger B. Nalmefene and alcohol dependence: a new approach or the same old unacceptable marketing? Subst Abuse Rehabil. 2015;6:75–80.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Palpacuer C, Laviolle B, Boussageon R, Reymann JM, Bellissant E, Naudet F. Risks and benefits of nalmefene in the treatment of adult alcohol dependence: a systematic literature review and meta-analysis of published and unpublished double-blind randomized controlled trials. PLoS Med. 2015;12(12):e1001924.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Braillon A. Nalmefene in alcohol misuse: junk evaluation by the European Medicines Agency. BMJ. 2014;348:g2017.

    Article  PubMed  Google Scholar 

  5. Spence D. Bad medicine: nalmefene in alcohol misuse. BMJ. 2014;348:g1531.

    Article  PubMed  Google Scholar 

  6. Naudet F, Granger B, Braillon A. Cost-effectiveness of nalmefene: exaggerated expectations or fallacy? Alcohol Alcohol. 2016. doi:10.1093/alcalc/agw029 (Online Jun 3)

  7. Fitzgerald N, Angus K, Elders A, de Andrade M, Raistrick D, Heather N, McCambridge J. Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers. Addiction. 2016;111(8):1477–87. doi:10.1111/add.13438

  8. Muckle W, Muckle J, Welch V, Tugwell P. Managed alcohol as a harm reduction response for alcohol addiction in populations at high risk for substance abuse. Cochrane Database Syst Rev. 2012;12:CD006747.

  9. Rivollier F, Masson M. Manic symptoms induced by high doses of baclofen: a case report. Encephale. 2016. doi:10.1016/j.encep.2016.03.015 (Online Jun 9).

  10. Olivier PY, Joyeux-Faure M, Gentina T, Launois SH, d’Ortho MP, Pépin JL, Gagnadoux F. Severe central sleep apnea associated with chronic baclofen therapy: a case series. Chest. 2016;149(5):e127–31.

    Article  PubMed  Google Scholar 

  11. Braillon A, Lexchin J. Off-label drug use: whose interests are served? Am J Med Qual. 2016;31(3):285.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Alain Braillon.

Ethics declarations

Funding

No sources of funding were used in the preparation of this letter.

Conflict of interest

Alain Braillon has no conflicts of interest that are directly relevant to the content of this letter.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Braillon, A. Comment on: “Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence”. Drug Saf 39, 1151–1152 (2016). https://doi.org/10.1007/s40264-016-0447-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-016-0447-4

Keywords

Navigation